SCHEMBL64239

SCHEMBL64239

Cc1cc(CNC(=O)c2nc3n(c(=O)c2O)CC2CCC3(NC(=O)Nc3ccccn3)CC2)ccc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.39
MMP13 P45452 5/20 0.36
KCNH2 Q12809 1/20 0.35
CYP2C9 P11712 1/20 0.35
MAP3K5 Q99683 1/20 0.34
RAB9A P51151 2/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
EPHX2 P34913 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
MMP10 P09238 1/20 0.32
MMP8 P22894 1/20 0.32
HCRTR1 O43613 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL62729 0.90 KCNH2 (0.42) PPARGKCNH2CYP2C9RAB9ATSHR
SCHEMBL64237 0.90 MMP13 (0.40) PPARGMMP13KCNH2CYP2C9MAPK1
SCHEMBL62655 0.88 MMP13 (0.37) PPARGMMP13KCNH2CYP2C9MMP10
SCHEMBL64242 0.88 MMP13 (0.39) MMP13KCNH2CYP2C9KDM4EALDH1A1
SCHEMBL63867 0.88 NAMPT (0.40) MMP13KCNH2CYP2C9TSHREPHX2
SCHEMBL63874 0.86 CYP2C9 (0.38) PPARGMMP13KCNH2CYP2C9MMP10
SCHEMBL62253 0.84 MMP13 (0.37) MMP13KCNH2CYP2C9RAB9ANPC1
SCHEMBL64434 0.84 MMP13 (0.38) MMP13KCNH2CYP2C9KDM4EALDH1A1
SCHEMBL64216 0.84 HCRTR1 (0.39) MMP13KCNH2CYP2C9TSHRNPC1
SCHEMBL63858 0.83 MMP13 (0.37) PPARGMMP13KCNH2CYP2C9MMP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG PPARG 4688/4885MMP13 4137/4885KCNH2 3969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.